Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

Altres ajuts: The NIHR Imperial College BRC Push for Impact scheme 2019; the European Association for the Study of the Liver (Andrew Burroughs Fellowship); the Society of Immunotherapy of Cancer-AstraZeneca Young Investigator Award; the Wellcome Trust Strategic Fund (PS3416); the Associazione Italiana per la Ricerca sul Cancro (AIRC MFAG Grant ID 25697); the NIHR Imperial Biomedical Research Centre (BRC); the Imperial Experimental Cancer Medicine Centre (ECMC); the Imperial College Tissue Bank. the NIHR Imperial BRC. Introduction It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). However, it is unclear whether baseline BMI may influence outcomes from first-line chemoimmunotherapy combinations. Methods In this international multicenter study, we evaluated the association between baseline BMI, progression-free survival (PFS) and overall survival (OS) in a cohort of patients with stage IV NSCLC consecutively treated with first-line chemoimmunotherapy combinations. BMI was categorized according to WHO criteria. Results Among the 853 included patients, 5.3% were underweight; 46.4% were of normal weight; 33.8% were overweight; and 14.5% were obese. Overweight and obese patients were more likely aged ≥70 years (p=0.00085), never smokers (p